Psypal - Neue Hoffnung für Patient:innen dank EU Förderung
12 déc. 2024 07h00 HE
|
Avextra Pharma GmbH
BENSHEIM, Deutschland, Dec. 12, 2024 (GLOBE NEWSWIRE) -- Die erste vollständig von der EU finanzierte Psilocibin-Therapiestudie, hat nun die Zulassung der Europäischen Arzneimittel-Behörde EMA...
Avextra Supports First Fully EU-Funded Psilocybin Therapy Study, Now Approved by EMA
12 déc. 2024 07h00 HE
|
Avextra Pharma GmbH
Exclusive Industry Role: Avextra is the industry partner in the first EU-funded project focused on psychedelic-assisted therapy for patients in palliative care suffering from depression, with a total...
Avextra Portugal Unveils Advanced Breeding Program to Develop Proprietary THC and CBD Cultivars, Establishing a Key IP Pillar
20 nov. 2024 07h00 HE
|
Avextra AG
Avextra Portugal launches an innovative in-house breeding program to develop proprietary cannabis varieties with specific, consistent and reproducible cannabinoid and terpene profiles.Over a two-year...
Avextra Announces the Approval of NEUROBIS by the Italian Medicines Agency: A Phase II Clinical Trial Using a Proprietary Cannabis-based Medicine for the Treatment of the Symptoms of Neurodegenerative Diseases
08 oct. 2024 07h00 HE
|
Avextra AG
The Italian Medicines Agency AIFA and the Italian Ministry of Health have granted formal approval for NEUROBIS; a multi-centre Phase II study to evaluate safety, and efficacy of an Avextra oral...
Avextra annuncia l’approvazione da parte dell'Agenzia Italiana del Farmaco (AIFA) di NEUROBIS uno studio clinico di Fase II che utilizza estratto di cannabis AVEXTRA per il trattamento delle malattie neurodegenerative
08 oct. 2024 07h00 HE
|
Avextra AG
L'Agenzia Italiana del Farmaco (AIFA) e il Ministero della Salute hanno approvato ufficialmente NEUROBIS: uno studio multicentrico di Fase II per valutare la sicurezza e l'efficacia di una...
Avextra AG and SynQube GmbH announce a Strategic Partnership in Drug Development with Cannabinoids and other Psychotropic Substances
20 juin 2024 01h00 HE
|
Avextra AG
Avextra, the leading European vertically-integrated manufacturer and developer of cannabis-based medicines, is expanding its pharmaceutical development capabilities. Behind SynQube GmbH are the two...
Avextra und SynQube GmbH geben eine strategische Partnerschaft in der Arzneimittelentwicklung mit Cannabinoiden und anderen psychotropen Substanzen bekannt
20 juin 2024 01h00 HE
|
Avextra AG
Avextra, der führende europäische vertikal integrierte Hersteller und Entwickler von Medikamenten auf Cannabisbasis, erweitert nach Abschluss seiner Finanzierungsrunde im ersten Quartal 2024 seine...
Avextra AG and SynQube GmbH announce a Strategic Partnership in Drug Development with Cannabinoids and other Psychotropic Substances
20 juin 2024 01h00 HE
|
Avextra AG
Avextra, the leading European vertically-integrated manufacturer and developer of cannabis-based medicines is expanding its pharmaceutical development capabilities. Behind SynQube GmbH are the two...
Avextra AG Announces Closing of Follow-On Capital Raise Supported by Existing and New Institutional Investors
07 févr. 2024 07h00 HE
|
Avextra AG
Avextra AG Announces Closing of Follow-On Capital Raise Supported by Existing and New Institutional Investors
German Pain Association (DGS) and Pharmaceutical Company Avextra Join Forces to Launch Their New Study OCEAN
23 janv. 2024 03h30 HE
|
Avextra AG
German Pain Association (DGS) and Pharmaceutical Company Avextra Join Forces to Launch Their New Study OCEAN